DANYELZA® and Indicated Disease State
The purpose of this module is first to provide an introduction to neuroblastoma, the treatment for high-risk neuroblastoma, and targeting GD2 in neuroblastoma. Secondly, it will familiarize you with the mechanism of action of DANYELZA® and the results from the key clinical trials that led to the conditional FDA approval of DANYELZA®. Lastly, it will highlight the most common adverse reactions associated with DANYELZA® administration.
Please see Important Safety Information including Boxed Warning on serious infusion-related reactions and neurotoxicity.
DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutic, Inc.